Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications (MIRPROT)
A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device.
The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.|
- Depressive symptoms remission or response rates, under usual SSRI treatment. [ Time Frame: 10 weeks of follow up ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Subjects and patients will be asked to give blood samples at 4 points of time for the lab processing: micro-RNA and proteome profiling/
|Study Start Date:||November 2011|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
Controls: Volunteers that had clinical screening with no depression diagnosis.
Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01681407
|Contact: Amichai I Hareven, MDemail@example.com|
|HaEmek Medical Center||Recruiting|
|Contact: Amichai I Hareven, MD 972544461022 firstname.lastname@example.org|
|Principal Investigator: Amichai I Hareven, MD|